Product Description
Mechanisms of Action: DPP4 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Russia
Approved Indications: None
Company: Pfizer
Company Location: Eastern America
Company Founding Year: 1849
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Type 2 Diabetes
Phase 1: Kidney Failure, Chronic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00596518 |
A7941014 | P1 |
Completed |
Kidney Failure, Chronic |
2008-07-01 |
2019-03-22 |
Treatments |
|
2007-007588-26 |
2007-007588-26 | P2 |
Completed |
Type 2 Diabetes |
2008-08-26 |
2022-03-12 |
Treatments |
|
NCT00618007 |
A7941006 | P2 |
Completed |
Type 2 Diabetes |
2008-08-01 |
2019-03-18 |
Treatments |
|
2007-001922-28 |
2007-001922-28 | P2 |
Completed |
Type 2 Diabetes |
2008-06-26 |
2025-07-05 |
Treatments |
|
NCT00473525 |
A7941005 | P2 |
Completed |
Type 2 Diabetes |
2008-06-01 |
2019-03-21 |
Treatments |
|
NCT03088670 |
SRX-1374-02 | P3 |
Completed |
Type 2 Diabetes |
2014-03-30 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|
